Drug Trial Radar · NCT02206204
Study of Selexipag and Its Metabolite ACT-333679 on Cardiac Repolarization in Healthy Male and Female Subjects
Last checked: Nov 20, 2026Latest source record: Aug 1, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
159
Actual
Start
Jun 2012
Primary completion
Nov 2012
Study completion Nov 2012
Sponsor
- Lead sponsor
- ActelionJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Aug 1, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a single-center, double-blind, randomized, placebo- and positive-controlled, double-dummy, parallel-group, multiple-dose, up-titration study with a nested cross-over comparison between moxifloxacin and placebo in healthy male and female subjects. The primary objective is to demonstrate that selexipag and its metabolite ACT-333679 do not have an effect on cardiac repolarization exceeding the threshold of regulatory concern, at two orally administered dose levels (800 and 1600 μg twice daily) in healthy male and female subjects. Moxifloxacin is included as a positive control.
Conditions
- Cardiodynamics
- Safety
- Tolerability
- Pharmacokinetics
Interventions
selexipagDrug
placebo for selexipagDrug
moxifloxacinDrug
moxifloxacin-matching placeboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Baseline adjusted placebo corrected change in corrected QTc interval (time interval from beginning of the Q wave until end of the T wave) (ΔΔQTcI) at various time pointsTime frame: 24 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Covance Clinical Research Unit
Evansville, Indiana
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.